Back to results
US 12,595,302 B2Granted
CLDN18.2 binding molecule
AssigneeSanyou Biopharmaceuticals Co., Ltd.
InventorsYongcong Tan, Guojun Lang, Chao Kong, Chanjuan Liu, Min Deng, Qi Wu, Jing Zhang, Wenhai Zhang, Baoguo Fan
Life of this patent
Estimating the term…
Abstract
Disclosed is a novel CLDN18.2 binding molecule. Also disclosed are a nucleic acid molecule encoding the CLDN18.2 binding molecule, an expression vector and a host cell for expressing the CLDN18.2 binding molecule. Further disclosed are a method for producing the CLDN18.2 binding molecule and use thereof.
Claims12
A CLDN18.2 binding molecule, which is a VHH single domain antibody or a VHH-Fc antibody, wherein the VHH comprises a CDR1, a CDR2 and a CDR3 selected from the following groups, wherein:
- (a) the CDR1 has the amino acid sequence as shown in SEQ ID NO:
- 30, the CDR2 has the amino acid sequence as shown in SEQ ID NO:
- 31, and the CDR3 has the amino acid sequence as shown in SEQ ID NO:
- 32;
- (b) the CDR1 has the amino acid sequence as shown in SEQ ID NO:
- 1, the CDR2 has the amino acid sequence as shown in SEQ ID NO:
- 2, and the CDR3 has the amino acid sequence as shown in SEQ ID NO:
- 3;
- (c) the CDR1 has the amino acid sequence as shown in SEQ ID NO:
- 1, the CDR2 has the amino acid sequence as shown in SEQ ID NO:
- 2, and the CDR3 has the amino acid sequence as shown in SEQ ID NO:
- 6;
- (d) the CDR1 has the amino acid sequence as shown in SEQ ID NO:
- 1, the CDR2 has the amino acid sequence as shown in SEQ ID NO:
- 4, and the CDR3 has the amino acid sequence as shown in SEQ ID NO:
- 5;
- (e) the CDR1 has the amino acid sequence as shown in SEQ ID NO:
- 30, the CDR2 has the amino acid sequence as shown in SEQ ID NO:
- 31, and the CDR3 has the amino acid sequence as shown in SEQ ID NO:
- 37;
- (f) the CDR1 has the amino acid sequence as shown in SEQ ID NO:
- 33, the CDR2 has the amino acid sequence as shown in SEQ ID NO:
- 31, and the CDR3 has the amino acid sequence as shown in SEQ ID NO:
- 62;
- (g) the CDR1 has the amino acid sequence as shown in SEQ ID NO:
- 33, the CDR2 has the amino acid sequence as shown in SEQ ID NO:
- 31, and the CDR3 has the amino acid sequence as shown in SEQ ID NO:
- 37;
- (h) the CDR1 has the amino acid sequence as shown in SEQ ID NO:
- 34, the CDR2 has the amino acid sequence as shown in SEQ ID NO:
- 31, and the CDR3 has the amino acid sequence as shown in SEQ ID NO:
- 37;
- (i) the CDR1 has the amino acid sequence as shown in SEQ ID NO:
- 35, the CDR2 has the amino acid sequence as shown in SEQ ID NO:
- 31, and the CDR3 has the amino acid sequence as shown in SEQ ID NO:
- 62;
- (j) the CDR1 has the amino acid sequence as shown in SEQ ID NO:
- 36, the CDR2 has the amino acid sequence as shown in SEQ ID NO:
- 31, and the CDR3 has the amino acid sequence as shown in SEQ ID NO:
- 62;
- (k) the CDR1 has the amino acid sequence as shown in SEQ ID NO:
- 38, the CDR2 has the amino acid sequence as shown in SEQ ID NO:
- 31, and the CDR3 has the amino acid sequence as shown in SEQ ID NO:
- 62;
- (l) the CDR1 has the amino acid sequence as shown in SEQ ID NO:
- 39, the CDR2 has the amino acid sequence as shown in SEQ ID NO:
- 41, and the CDR3 has the amino acid sequence as shown in SEQ ID NO:
- 37;
- or
- (m) the CDR1 has the amino acid sequence as shown in SEQ ID NO:
- 40, the CDR2 has the amino acid sequence as shown in SEQ ID NO:
- 31, and the CDR3 has the amino acid sequence as shown in SEQ ID NO:
- 37.
50 more elements
Dependencies are inferred from the claim text.